

Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Interferon Therapy, Maloti Lipid, Nucleoside Analog), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2020-2030F

<https://marketpublishers.com/r/L517ABDA9C87EN.html>

Date: February 2025

Pages: 185

Price: US\$ 4,500.00 (Single User License)

ID: L517ABDA9C87EN

Abstracts

Global Liver Fibrosis Drugs Market was valued at USD 18.98 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.98% through 2030. The Global Liver Fibrosis Drugs Market refers to the pharmaceutical industry's segment dedicated to developing and distributing medications aimed at treating liver fibrosis. Liver fibrosis is a progressive condition characterized by the accumulation of scar tissue in the liver, often resulting from chronic liver diseases such as hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease.

Key Market Drivers

Rising Prevalence of Liver Diseases

The Global Liver Fibrosis Drugs Market is experiencing significant growth, and one of the key drivers behind this expansion is the alarming rise in the prevalence of liver diseases worldwide. Liver disease is responsible for over two million deaths each year, representing 4% of global mortality—equivalent to 1 in every 25 deaths worldwide. Among these, one-third of liver-related fatalities occur in females, highlighting a significant gender-specific impact. Additionally, liver cancer alone accounts for approximately 600,000 to 900,000 deaths annually, underscoring its critical role in the

global burden of liver disease. Liver diseases, encompassing a range of conditions from viral hepatitis to non-alcoholic fatty liver disease (NAFLD), are posing a growing health threat. Alcohol consumption remains a primary driver of cirrhosis worldwide, with an even higher prevalence in high-income countries. In contrast, Asia accounts for 75% of all liver cancer cases, predominantly linked to chronic Hepatitis B (HBV) and Hepatitis C (HCV) infections, highlighting a region-specific disease burden and the need for targeted healthcare interventions.

Liver diseases are on the rise, affecting millions of individuals across the globe. In 2022, chronic Hepatitis B and C led to approximately 1.3 million deaths globally, averaging 3,500 fatalities per day. An estimated 254 million individuals are living with Hepatitis B, while 50 million are affected by Hepatitis C. Additionally, 6,000 new infections occur daily, underscoring the persistent global health challenge posed by viral hepatitis. Chronic hepatitis B and C infections, excessive alcohol consumption, obesity, and metabolic disorders have all contributed to the surge in liver disease cases. These conditions can cause liver inflammation and damage, ultimately leading to the development of liver fibrosis.

Liver fibrosis is often referred to as a 'silent' condition because it progresses silently without overt symptoms until it reaches an advanced stage. During this silent progression, significant damage can occur. As awareness grows about the link between liver diseases and fibrosis, more healthcare providers are actively screening patients for early signs of fibrosis. This increased vigilance is spurring the demand for liver fibrosis drugs to intervene at an earlier stage.

Liver fibrosis is a common consequence of chronic liver diseases. As these diseases progress, they cause ongoing liver injury, triggering the body's natural response to repair damaged tissue, which includes the formation of scar tissue. Over time, this fibrosis can accumulate and impair liver function. Recognizing the close association between liver diseases and fibrosis is driving both clinicians and pharmaceutical companies to prioritize the development and use of liver fibrosis drugs.

Liver fibrosis is a precursor to cirrhosis, a more severe and irreversible condition. Cirrhosis can lead to liver failure and increase the risk of liver cancer. Preventing the progression of fibrosis to cirrhosis is a primary goal in managing liver diseases. Liver fibrosis drugs are designed to slow down or even reverse the fibrotic process, offering hope to patients in avoiding the direst consequences of liver disease.

The rising prevalence of liver diseases has spurred pharmaceutical companies to invest

in research and development efforts to create innovative liver fibrosis drugs. These drugs are often categorized as antifibrotic agents, and they target the fibrotic tissue in the liver directly. The expanding range of treatment options provides healthcare professionals with more tools to address liver fibrosis effectively.

The economic burden of liver diseases is substantial. Advanced liver diseases, including fibrosis and cirrhosis, necessitate expensive medical interventions such as liver transplantation and long-term healthcare. In the United States, the annual healthcare costs associated with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) are estimated to range between USD16,744 and USD300,408 per patient. This results in a total economic burden of approximately USD15.7 billion per year, highlighting the substantial financial impact of these liver diseases on the U.S. healthcare system. As the number of individuals affected by liver diseases increases, so does the financial strain on healthcare systems. Investing in liver fibrosis drugs to prevent disease progression can mitigate these financial burdens.

Growing Awareness and Early Detection

The Global Liver Fibrosis Drugs Market is witnessing remarkable growth, and a significant catalyst behind this expansion is the increasing awareness of liver diseases and the emphasis on early detection. On Friday, April 19, the global community will unite to observe World Liver Day, an essential initiative dedicated to increasing awareness of liver health and the rising burden of liver diseases worldwide. This initiative is spearheaded by the European Association for the Study of the Liver (EASL), the Asian Pacific Association for the Study of the Liver (APASL), the American Association for the Study of Liver Diseases (AASLD), the Asociación Latinoamericana para el Estudio del Hígado (ALEH), and the Society on Liver Disease in Africa (SOLDA). These organizations collaborate under the Healthy Livers, Healthy Lives Coalition, emphasizing the need for global action in liver disease prevention and treatment. Liver fibrosis, a condition characterized by the accumulation of scar tissue in the liver, often arises from chronic liver diseases like hepatitis, fatty liver disease, and alcohol-induced liver damage. The prevalence of Steatotic Liver Disease (SLD), characterized by macrovesicular steatosis affecting 5% or more of the liver, stands at 40.1%. Additionally, 14.8% of individuals exhibit some degree of liver fibrosis, while 2.1% have progressed to cirrhosis, underscoring the widespread impact of liver disease.

Awareness campaigns and educational initiatives have played a pivotal role in enhancing public understanding of liver diseases. Individuals are becoming more

cognizant of the risk factors, symptoms, and consequences associated with liver conditions. Increased awareness has led to a greater willingness to seek medical attention and undergo regular screenings.

One of the most critical factors in effectively managing liver diseases and fibrosis is early diagnosis. Routine check-ups and liver function tests can help detect liver abnormalities in their early stages. When liver diseases are identified early, interventions can be initiated promptly, potentially halting the progression of fibrosis and preventing severe complications like cirrhosis and liver failure.

Aware patients are more likely to engage in conversations with healthcare providers about their liver health. They are also more likely to adhere to recommended screening and treatment regimens. As patients become advocates for their own well-being, healthcare providers can work collaboratively to manage liver diseases more effectively.

Advancements in medical technology have given rise to non-invasive diagnostic methods that can assess the extent of liver fibrosis without the need for invasive procedures such as liver biopsy. Non-invasive tests, such as elastography and blood biomarker panels, offer a more patient-friendly alternative, making it easier for individuals to get screened for liver fibrosis.

Growing awareness and early detection not only benefit patients but also influence treatment strategies. When liver fibrosis is diagnosed in its early stages, clinicians have more treatment options at their disposal. Antifibrotic drugs, which target the underlying mechanisms of fibrosis, can be administered to slow or reverse the fibrotic process. The availability of such treatments is contributing to the growth of the liver fibrosis drugs market.

Many countries and healthcare organizations have launched public health initiatives to combat liver diseases. These initiatives focus on increasing awareness, encouraging preventive measures, and promoting early detection through screening programs. Such efforts are instrumental in driving more individuals to seek medical attention and access liver fibrosis drugs when needed.

Advancements in Drug Development

The Global Liver Fibrosis Drugs Market is experiencing robust growth, and at the heart of this expansion are the advancements in drug development. Liver fibrosis, characterized by the accumulation of scar tissue in the liver, is a progressive condition

often resulting from chronic liver diseases like hepatitis, fatty liver disease, and alcoholic liver disease.

One of the key factors boosting the liver fibrosis drugs market is the shift toward targeted drug development. Pharmaceutical companies are increasingly focusing on creating drugs that specifically address the mechanisms driving liver fibrosis. These antifibrotic drugs target the processes involved in fibrotic tissue formation, slowing down or even reversing the progression of fibrosis.

Advancements in our understanding of the molecular and cellular mechanisms underlying liver fibrosis have paved the way for more effective drug development. Researchers are continually identifying new drug targets and exploring innovative mechanisms of action that can disrupt fibrotic pathways. This increased knowledge has led to the development of drugs that are more potent and specific in their action.

Another significant development in the liver fibrosis drugs market is the exploration of combination therapies. Combining antifibrotic drugs with antiviral medications, for example, can address both the underlying cause of fibrosis (such as hepatitis) and the fibrosis itself. Such combination therapies can provide synergistic benefits, potentially improving treatment outcomes and driving market growth.

Advancements in drug development are also extending to the realm of biomarker discovery. Biomarkers are measurable indicators in the body that can signal the presence and severity of liver fibrosis. The identification of reliable biomarkers enables earlier diagnosis and better monitoring of disease progression, allowing for more precise and tailored treatments.

Innovations in drug development have led to the creation of non-invasive diagnostic tools for liver fibrosis assessment. Techniques such as elastography and blood biomarker panels provide accurate assessments of fibrosis severity without the need for invasive procedures like liver biopsy. These tools enhance patient comfort and compliance while enabling more frequent monitoring of fibrosis progression.

Pharmaceutical companies are increasingly collaborating with regulatory agencies to expedite the clinical trial and approval process for liver fibrosis drugs. Fast-track designations and priority review status are granted to promising drug candidates, allowing quicker access to innovative treatments. This streamlined process accelerates the time it takes for drugs to reach the market.

The growing prevalence of liver diseases and the potential market demand for effective treatments have attracted increased investment from pharmaceutical companies. The recognition of liver fibrosis as a critical health concern has spurred greater funding for research and development efforts, leading to the creation of more advanced drugs.

Expanding Access to Healthcare

The Global Liver Fibrosis Drugs Market is experiencing significant growth, and a crucial factor contributing to this expansion is the increasing access to healthcare services worldwide. Liver fibrosis, characterized by the accumulation of scar tissue in the liver, often results from chronic liver diseases such as hepatitis, fatty liver disease, and alcoholic liver disease.

Access to healthcare services has been a longstanding challenge in many parts of the world. However, ongoing efforts by governments, non-governmental organizations, and healthcare providers are steadily closing this gap. As more people gain access to healthcare facilities, they are more likely to be diagnosed and treated for liver diseases, including liver fibrosis.

One of the most significant benefits of improved access to healthcare is the ability to diagnose liver diseases and fibrosis at earlier stages. Routine check-ups, screenings, and liver function tests become more accessible to the population, leading to early detection and timely intervention. Early diagnosis is essential in halting the progression of fibrosis and preventing severe complications.

Expanding access to healthcare allows for the implementation of screening programs targeting high-risk populations. Individuals with a history of hepatitis, alcohol abuse, obesity, or other risk factors can be identified and screened for liver diseases. This proactive approach not only improves health outcomes but also increases the demand for liver fibrosis drugs.

Access to healthcare services also enables healthcare providers to educate patients about preventive measures for liver diseases. Lifestyle modifications, vaccination against hepatitis, and counseling on alcohol consumption are among the strategies that can be promoted. Preventive measures can reduce the incidence of liver diseases, ultimately leading to a reduced burden of fibrosis.

Advanced liver diseases and fibrosis often require specialized care and treatment. Expanding access to healthcare ensures that individuals with liver conditions have

access to hepatologists, gastroenterologists, and other specialists who can provide the necessary expertise. This access to specialized care enhances the management of liver fibrosis and related conditions.

Key Market Challenges

Complexity of Liver Fibrosis

Liver fibrosis is a multifaceted condition with various underlying causes and stages. The complexity arises from the numerous pathways involved in fibrosis development, making it challenging to target with a single therapeutic approach. As a result, drug development efforts must encompass a broad spectrum of mechanisms, increasing research complexity and costs.

Long and Costly Clinical Trials

Developing and testing liver fibrosis drugs is a protracted and resource-intensive process. Clinical trials require significant investments of time and money, and these trials must often be conducted over an extended duration to assess long-term safety and efficacy. High costs and lengthy timelines can deter pharmaceutical companies from entering the market.

Limited Treatment Options

While there have been advancements in liver fibrosis drug development, the market still lacks a wide array of treatment options. This limitation leaves healthcare providers with limited choices for tailoring therapies to individual patient needs. Expanding the range of effective treatments remains a challenge.

Key Market Trends

Advanced Antifibrotic Therapies

One of the most prominent trends in the liver fibrosis drugs market is the development of advanced antifibrotic therapies. These therapies target the underlying mechanisms of fibrosis, aiming to halt or even reverse its progression. With ongoing research into novel compounds and therapeutic approaches, we can expect to see more effective and targeted antifibrotic drugs entering the market.

Non-Invasive Diagnostic Tools

Non-invasive diagnostic tools are revolutionizing the way liver fibrosis is assessed. Techniques like elastography and blood biomarker panels provide accurate assessments of fibrosis severity without the need for invasive procedures such as liver biopsy. The adoption of these tools is expected to increase, enabling more frequent monitoring of fibrosis progression.

Biotechnology Advancements

Biotechnology is playing a pivotal role in liver fibrosis drug development. Innovative biotechnological approaches, such as gene therapy and monoclonal antibodies, are being explored as potential treatments. These cutting-edge techniques hold promise for more targeted and precise therapies.

Segmental Insights

Drug Class Insights

Based on the category of drug class, nucleoside analogs was the fastest-growing segment in the Global Liver Fibrosis Drugs Market and are expected to maintain their stronghold throughout the forecast years. Their proven efficacy in suppressing fibrosis progression and improving liver function has garnered significant clinical support, positioning them as a key treatment option. As chronic liver diseases continue to rise globally, the demand for effective treatments is surging, and nucleoside analogs provide a promising solution.

Their established safety profiles, manageable side effects, and ability to improve patient compliance make them a preferred choice for long-term treatment plans. Furthermore, ongoing research and development are likely to produce innovative nucleoside analog formulations, further boosting their dominance in this critical healthcare segment. These factors indicate that nucleoside analogs will continue to see strong growth and maintain a competitive advantage in the fight against liver fibrosis..

Regional Insights

North America was poised to maintain its dominance in the Global Liver Fibrosis Drugs Market for several compelling reasons. The region boasts a robust healthcare infrastructure and a well-established pharmaceutical industry, which enables rapid drug

development, regulatory approvals, and efficient distribution networks. North America has a higher prevalence of liver diseases due to factors like obesity, alcohol consumption, and viral hepatitis, which results in a larger patient pool seeking treatment. Additionally, the region's strong focus on research and development, as well as its ability to attract top talent and investment, ensures that innovative liver fibrosis drugs continue to emerge. Moreover, favorable reimbursement policies and a greater awareness of liver diseases contribute to the sustained growth of this market. With these factors in play, North America is well-positioned to lead the way in liver fibrosis drug advancements and market dominance.

Key Market Players

Gilead Sciences Inc

Merck & Co Inc

Bristol-Myers Squibb Co

Johnson & Johnson Services, Inc.

Novartis AG

Vertex Pharmaceuticals Inc

Pfizer Inc

FibroGen Inc

Pharmaxis Ltd

Report Scope:

In this report, the Global Liver Fibrosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liver Fibrosis Drugs Market, By Drug Class:

Interferon Therapy

Maloti Lipid

Nucleoside Analog

Liver Fibrosis Drugs Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Liver Fibrosis Drugs Market, By Region:

North America

United States

Canada

Mexico

Europe

Germany

United Kingdom

France

Italy

Spain

Asia-Pacific

China

Japan

India

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Liver Fibrosis Drugs Market.

Available Customizations:

Global Liver Fibrosis Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL LIVER FIBROSIS DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Drug Class (Interferon Therapy, Maloti Lipid, Nucleoside Analog)
 - 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
 - 5.2.3. By Region

- 5.2.4. By Company (2024)
- 5.3. Product Market Map
 - 5.3.1. By Drug Class
 - 5.3.2. By Distribution Channel
 - 5.3.3. By Region

6. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Drug Class
 - 6.2.2. By Distribution Channel
 - 6.2.3. By Country
- 6.3. North America: Country Analysis
 - 6.3.1. United States Liver Fibrosis Drugs Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Drug Class
 - 6.3.1.2.2. By Distribution Channel
 - 6.3.2. Canada Liver Fibrosis Drugs Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Drug Class
 - 6.3.2.2.2. By Distribution Channel
 - 6.3.3. Mexico Liver Fibrosis Drugs Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Drug Class
 - 6.3.3.2.2. By Distribution Channel

7. EUROPE LIVER FIBROSIS DRUGS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast

- 7.2.1. By Drug Class
- 7.2.2. By Distribution Channel
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
 - 7.3.1. Germany Liver Fibrosis Drugs Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Drug Class
 - 7.3.1.2.2. By Distribution Channel
 - 7.3.2. United Kingdom Liver Fibrosis Drugs Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Drug Class
 - 7.3.2.2.2. By Distribution Channel
 - 7.3.3. France Liver Fibrosis Drugs Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Drug Class
 - 7.3.3.2.2. By Distribution Channel
 - 7.3.4. Italy Liver Fibrosis Drugs Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Drug Class
 - 7.3.4.2.2. By Distribution Channel
 - 7.3.5. Spain Liver Fibrosis Drugs Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Drug Class
 - 7.3.5.2.2. By Distribution Channel

8. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Drug Class

8.2.2. By Distribution Channel

8.2.3. By Country

8.3. Asia-Pacific: Country Analysis

8.3.1. China Liver Fibrosis Drugs Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Drug Class

8.3.1.2.2. By Distribution Channel

8.3.2. Japan Liver Fibrosis Drugs Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Drug Class

8.3.2.2.2. By Distribution Channel

8.3.3. India Liver Fibrosis Drugs Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Drug Class

8.3.3.2.2. By Distribution Channel

8.3.4. Australia Liver Fibrosis Drugs Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Drug Class

8.3.4.2.2. By Distribution Channel

8.3.5. South Korea Liver Fibrosis Drugs Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Drug Class

8.3.5.2.2. By Distribution Channel

9. SOUTH AMERICA LIVER FIBROSIS DRUGS MARKET OUTLOOK

9.1. Market Size & Forecast

- 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Drug Class
 - 9.2.2. By Distribution Channel
 - 9.2.3. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Liver Fibrosis Drugs Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Drug Class
 - 9.3.1.2.2. By Distribution Channel
 - 9.3.2. Argentina Liver Fibrosis Drugs Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Drug Class
 - 9.3.2.2.2. By Distribution Channel
 - 9.3.3. Colombia Liver Fibrosis Drugs Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Drug Class
 - 9.3.3.2.2. By Distribution Channel

10. MIDDLE EAST AND AFRICA LIVER FIBROSIS DRUGS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Drug Class
 - 10.2.2. By Distribution Channel
 - 10.2.3. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Liver Fibrosis Drugs Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Drug Class

- 10.3.1.2.2. By Distribution Channel
- 10.3.2. Saudi Arabia Liver Fibrosis Drugs Market Outlook
 - 10.3.2.1. Market Size & Forecast
 - 10.3.2.1.1. By Value
 - 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Drug Class
 - 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Liver Fibrosis Drugs Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Drug Class
 - 10.3.3.2.2. By Distribution Channel
- 10.3.4. Kuwait Liver Fibrosis Drugs Market Outlook
 - 10.3.4.1. Market Size & Forecast
 - 10.3.4.1.1. By Value
 - 10.3.4.2. Market Share & Forecast
 - 10.3.4.2.1. By Drug Class
 - 10.3.4.2.2. By Distribution Channel

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Development
- 12.2. Mergers & Acquisitions
- 12.3. Product Launches

13. PORTER'S FIVE FORCES ANALYSIS

- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products

14. COMPETITIVE LANDSCAPE

14.1. Gilead Sciences Inc.

14.1.1. Business Overview

14.1.2. Product Offerings

14.1.3. Recent Developments

14.1.4. Financials (As Reported)

14.1.5. Key Personnel

14.1.6. SWOT Analysis

14.2. Merck & Co Inc

14.3. Bristol-Myers Squibb Co

14.4. Johnson & Johnson Services, Inc.

14.5. Novartis AG

14.6. Vertex Pharmaceuticals Inc

14.7. Pfizer Inc

14.8. FibroGen Inc

14.9. Pharmaxis Ltd

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

I would like to order

Product name: Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Interferon Therapy, Maloti Lipid, Nucleoside Analog), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region & Competition, 2020-2030F

Product link: <https://marketpublishers.com/r/L517ABDA9C87EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L517ABDA9C87EN.html>